View Financial HealthPharmanutra 배당 및 자사주 매입배당 기준 점검 2/6Pharmanutra 수익으로 충분히 충당되는 현재 수익률 1.39% 보유한 배당금 지급 회사입니다.핵심 정보1.4%배당 수익률0.1%자사주 매입 수익률총 주주 수익률1.5%미래 배당 수익률2.4%배당 성장률14.8%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향58%최근 배당 및 자사주 매입 업데이트공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.1%).모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.공시 • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.공시 • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.공시 • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.Buy Or Sell Opportunity • Nov 07Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €53.40. The fair value is estimated to be €43.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 29% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.Reported Earnings • Sep 11Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.Buy Or Sell Opportunity • Aug 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to €50.90. The fair value is estimated to be €42.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 3.2%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.Reported Earnings • May 17First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.1%).Reported Earnings • Mar 17Full year 2023 earnings released: EPS: €1.33 (vs €1.56 in FY 2022)Full year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.공시 • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.Reported Earnings • Sep 13Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.Board Change • Jul 26Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. President of Supervisory Board Michele Giordano was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, 761 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: 761 의 배당금 지급이 증가했지만 회사는 8 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Pharmanutra 배당 수익률 vs 시장761의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (761)1.4%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.6%업계 평균 (Personal Products)2.5%분석가 예측 (761) (최대 3년)2.4%주목할만한 배당금: 761 의 배당금( 1.39% )은 German 시장에서 배당금 지급자의 하위 25%( 1.49% )와 비교해 주목할 만하지 않습니다.고배당: 761 의 배당금( 1.39% )은 German 시장에서 배당금 지급자의 상위 25%( 4.58% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 57.5% )을 통해 761 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 71.5% )로 761 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 10:52종가2026/05/27 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmanutra S.p.A.는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Anna FrontaniBerenbergAndrea RandoneIntermonte SIM S.p.A.Giorgio TavoliniIntermonte SIM S.p.A.3명의 분석가 더 보기
공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.1%).
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
공시 • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.
공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
공시 • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.
공시 • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
Buy Or Sell Opportunity • Nov 07Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €53.40. The fair value is estimated to be €43.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 29% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.
Reported Earnings • Sep 11Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
Buy Or Sell Opportunity • Aug 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to €50.90. The fair value is estimated to be €42.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 3.2%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 99% in the next 2 years.
Reported Earnings • May 17First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.1%).
Reported Earnings • Mar 17Full year 2023 earnings released: EPS: €1.33 (vs €1.56 in FY 2022)Full year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.
공시 • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Sep 13Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.
Board Change • Jul 26Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. President of Supervisory Board Michele Giordano was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.